Mbx Biosciences Inc (MBX)

$24.79 +0.72 (2.99%)
Market Cap 808.61M
Revenue (ttm) 0.00
Net Income (ttm) -61.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 617,700
Avg Vol 1,593,972
Day's Range N/A - N/A
Shares Out 33.59M
Stochastic %K 76%
Beta 1.20
Analysts Strong Sell
Price Target $58.25

Company Profile

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a...

Industry: Biotechnology
Sector: Healthcare
Phone: 317 659 0200
Website: mbxbio.com
Address:
11711 North Meridian Street, Suite 300, Carmel, United States
creativeflood
creativeflood Nov. 14 at 3:24 PM
$MBX watch the buyout announcement. Breaking up even in this market environment. Totally under the radar
1 · Reply
SocioCobb
SocioCobb Nov. 12 at 4:14 AM
$MBX 😎 👍
0 · Reply
DrwarrenB
DrwarrenB Nov. 11 at 2:10 PM
$MBX
0 · Reply
Pobr
Pobr Nov. 11 at 1:59 PM
$MBX is a compelling entry post-Phase 2. Canvuparatide met its primary endpoint, showing a 63% responder rate in Hypoparathyroidism (HP), significantly higher than placebo (31%). This validates their proprietary PEP™ platform. With a strong 'Strong Buy' consensus and average price targets hitting \mathbf{\$ 57-60}, the market hasn't fully factored in the once-weekly dosing advantage in the $1.3B HP market. The risk/reward profile is highly skewed to the upside. Position now. #MBX #Biotech #Investment"
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 2:57 PM
Guggenheim has updated their rating for MBX Biosciences ( $MBX ) to Buy with a price target of 77.
0 · Reply
DrWodo
DrWodo Nov. 7 at 6:36 PM
$MBX this thing is a beast- someone knows something 🤔
0 · Reply
RunnerSignals
RunnerSignals Nov. 6 at 9:20 PM
Market Warriors Rebound $URGN $ECX $CHGG $MBX flipped red to green like champs!
0 · Reply
d_risk
d_risk Nov. 6 at 4:45 PM
$MBX - MBX Biosciences, Inc. - 10Q - Updated Risk Factors MBX flags heightened risks from evolving R&D tax law under the One Big Beautiful Bill Act, expanded regulatory and reimbursement uncertainty post-Inflation Reduction Act and Chevron ruling, and warns that FDA or agency disruptions could stall product development and business operations. #Biotechnology #FDADisruption #HealthcareReimbursement #RegulatoryUncertainty #R&DTaxRisk 🟢 Added 🟠 Removed https://d-risk.ai/MBX/10-Q/2025-11-06
0 · Reply
DrWodo
DrWodo Nov. 6 at 4:19 PM
$MBX keep going!
0 · Reply
Doozio
Doozio Nov. 6 at 2:06 AM
$MBX the huckleberries are below the $$$ because it was always 🐒🍌🧠⏰♾️
0 · Reply
Latest News on MBX
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 6, 2025, 8:00 AM EST - 8 days ago

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 11 days ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MDGL MEDI

MBX Biosciences to Participate in November Investor Conferences

Oct 20, 2025, 8:00 AM EDT - 25 days ago

MBX Biosciences to Participate in November Investor Conferences

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

Sep 29, 2025, 8:00 AM EDT - 6 weeks ago

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Sep 25, 2025, 8:24 AM EDT - 7 weeks ago

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

RIG SFIX

MBX Biosciences, Inc. - Special Call

Sep 24, 2025, 9:27 PM EDT - 7 weeks ago

MBX Biosciences, Inc. - Special Call

MBX Biosciences Announces Pricing of Upsized Public Offering

Sep 24, 2025, 9:15 PM EDT - 7 weeks ago

MBX Biosciences Announces Pricing of Upsized Public Offering

MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market

Sep 22, 2025, 5:10 PM EDT - 7 weeks ago

MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market

MBX Biosciences Announces Proposed Public Offering

Sep 22, 2025, 4:14 PM EDT - 7 weeks ago

MBX Biosciences Announces Proposed Public Offering

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

Sep 22, 2025, 7:00 AM EDT - 7 weeks ago

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

Sep 19, 2025, 4:18 PM EDT - 2 months ago

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

Sep 4, 2025, 8:00 AM EDT - 2 months ago

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 2:00 PM EDT - 3 months ago

Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 7, 2025, 8:00 AM EDT - 3 months ago

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

Jun 23, 2025, 8:00 AM EDT - 5 months ago

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

Jun 16, 2025, 8:00 AM EDT - 5 months ago

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

Jun 10, 2025, 8:00 AM EDT - 5 months ago

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy

May 31, 2025, 7:24 AM EDT - 5 months ago

MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy

MBX Biosciences to Participate in June Investor Conferences

May 20, 2025, 8:00 AM EDT - 6 months ago

MBX Biosciences to Participate in June Investor Conferences

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 12, 2025, 8:00 AM EDT - 6 months ago

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

Apr 22, 2025, 8:00 AM EDT - 7 months ago

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 8:00 AM EDT - 8 months ago

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 17, 2025, 8:00 AM EDT - 8 months ago

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

MBX Biosciences Announces Additions to Leadership Team

Mar 5, 2025, 8:00 AM EST - 9 months ago

MBX Biosciences Announces Additions to Leadership Team

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

Mar 3, 2025, 8:00 AM EST - 9 months ago

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

MBX Biosciences to Participate in March Investor Conferences

Feb 18, 2025, 8:00 AM EST - 9 months ago

MBX Biosciences to Participate in March Investor Conferences

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

Jan 7, 2025, 7:00 AM EST - 11 months ago

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Nov 18, 2024, 8:00 AM EST - 1 year ago

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

MBX Biosciences to Participate in Upcoming November Investor Conferences

Oct 28, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in Upcoming November Investor Conferences

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

Sep 30, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 16, 2024, 4:05 PM EDT - 1 year ago

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

Sep 14, 2024, 5:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

BCAX GLXG TDTH XCH ZBIO

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

Sep 13, 2024, 12:36 PM EDT - 1 year ago

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

MBX Biosciences raises $163.2 mln in US IPO

Sep 12, 2024, 7:20 PM EDT - 1 year ago

MBX Biosciences raises $163.2 mln in US IPO

MBX Biosciences Announces Pricing of Initial Public Offering

Sep 12, 2024, 7:11 PM EDT - 1 year ago

MBX Biosciences Announces Pricing of Initial Public Offering

creativeflood
creativeflood Nov. 14 at 3:24 PM
$MBX watch the buyout announcement. Breaking up even in this market environment. Totally under the radar
1 · Reply
SocioCobb
SocioCobb Nov. 12 at 4:14 AM
$MBX 😎 👍
0 · Reply
DrwarrenB
DrwarrenB Nov. 11 at 2:10 PM
$MBX
0 · Reply
Pobr
Pobr Nov. 11 at 1:59 PM
$MBX is a compelling entry post-Phase 2. Canvuparatide met its primary endpoint, showing a 63% responder rate in Hypoparathyroidism (HP), significantly higher than placebo (31%). This validates their proprietary PEP™ platform. With a strong 'Strong Buy' consensus and average price targets hitting \mathbf{\$ 57-60}, the market hasn't fully factored in the once-weekly dosing advantage in the $1.3B HP market. The risk/reward profile is highly skewed to the upside. Position now. #MBX #Biotech #Investment"
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 2:57 PM
Guggenheim has updated their rating for MBX Biosciences ( $MBX ) to Buy with a price target of 77.
0 · Reply
DrWodo
DrWodo Nov. 7 at 6:36 PM
$MBX this thing is a beast- someone knows something 🤔
0 · Reply
RunnerSignals
RunnerSignals Nov. 6 at 9:20 PM
Market Warriors Rebound $URGN $ECX $CHGG $MBX flipped red to green like champs!
0 · Reply
d_risk
d_risk Nov. 6 at 4:45 PM
$MBX - MBX Biosciences, Inc. - 10Q - Updated Risk Factors MBX flags heightened risks from evolving R&D tax law under the One Big Beautiful Bill Act, expanded regulatory and reimbursement uncertainty post-Inflation Reduction Act and Chevron ruling, and warns that FDA or agency disruptions could stall product development and business operations. #Biotechnology #FDADisruption #HealthcareReimbursement #RegulatoryUncertainty #R&DTaxRisk 🟢 Added 🟠 Removed https://d-risk.ai/MBX/10-Q/2025-11-06
0 · Reply
DrWodo
DrWodo Nov. 6 at 4:19 PM
$MBX keep going!
0 · Reply
Doozio
Doozio Nov. 6 at 2:06 AM
$MBX the huckleberries are below the $$$ because it was always 🐒🍌🧠⏰♾️
0 · Reply
nbkihy8
nbkihy8 Nov. 6 at 1:12 AM
$MBX Up 34% in the past 30 days
0 · Reply
nbkihy8
nbkihy8 Nov. 4 at 5:40 PM
$MBX Up 20% since this post
0 · Reply
JarvisFlow
JarvisFlow Nov. 4 at 12:29 PM
TD Cowen updates rating for MBX Biosciences ( $MBX ) to Buy.
0 · Reply
__SquuezedChronometer_
__SquuezedChronometer_ Nov. 2 at 11:34 AM
Next major retail squeeze candidate right here $MBX $WRBY $CGNT $XELB 2
0 · Reply
Tradingistheway
Tradingistheway Oct. 31 at 1:52 PM
$MBX $100
0 · Reply
SocioCobb
SocioCobb Oct. 31 at 2:01 AM
$MBX 👍
0 · Reply
nbkihy8
nbkihy8 Oct. 30 at 3:46 PM
$MBX Major partnership? Buyout? Hmmm
0 · Reply
Jonita
Jonita Oct. 30 at 3:29 PM
$MBX in in
0 · Reply
Tradingistheway
Tradingistheway Oct. 30 at 3:06 PM
$MBX $35
0 · Reply
creativeflood
creativeflood Oct. 30 at 2:37 PM
$MBX 22.5s about to print
0 · Reply
creativeflood
creativeflood Oct. 30 at 2:04 PM
$MBX still think there is a buy out coming
0 · Reply
Tradingistheway
Tradingistheway Oct. 30 at 1:15 PM
$MBX $30?
0 · Reply